The FDA has approved tebentafusp-tebn (Kimmtrak) for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma.
Regulatory
FDA grants fast track designation to BNT111 for advanced melanoma
BNT111 (BioNTech) — an investigational cancer immunotherapy — uses a fixed combination of mRNA-encoded, tumor-associated antigens designed to activate a precise and strong immune response against cancer.
FDA Approves Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma Following CR
The FDA has approved pembrolizumab (Keytruda) for the adjuvant treatment of adult and pediatric patients with stage IIB or IIC melanoma following complete resection (CR).
FDA approves adjuvant Keytruda for certain adults, children with stage IIB, IIC melanoma
The FDA approved pembrolizumab as adjuvant therapy for adults and children aged 12 years or older with stage IIB or IIC melanoma after complete resection.